Physician profile
Randy Bowles
NPI 1851332860
$6,141.65
in general payments reported to CMS, 2019-2025
37 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $1,373 · 2021: $797 · 2022: $795 · 2023: $901 · 2024: $993 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,409.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $971.08 | 2019-2025 | Farxiga, Breztri, Bevespi Aerosphere |
| Novo Nordisk INC | $745.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $504.17 | 2019-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $475.20 | 2019-2024 | Mounjaro, Zepbound, Emgality |
| Abbvie INC. | $403.53 | 2019-2025 | Qulipta, Ubrelvy |
| Dexcom, INC. | $398.30 | 2021-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $360.81 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.48 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $175.03 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $166.95 | 2019-2023 | Verquvo, Belsomra |
| Kowa Pharmaceuticals America, INC. | $157.63 | 2019-2023 | Livalo, Seglentis |
| Janssen Pharmaceuticals, INC | $157.35 | 2019-2024 | Xarelto |
| Currax Pharmaceuticals LLC | $152.46 | 2020-2025 | Contrave, Onzetra Xsail |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.78 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $121.13 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Bowles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.